Endo CEO Blaise Coleman departs; Board member Scott Hirsch named Interim CEO

Endo LP

Blaise Coleman to step down as President & CEO and from the Board effective August 29, 2024; no disagreements cited.
Scott Hirsch, Board member since April 2024, appointed Interim CEO effective August 29; search underway for permanent CEO.
Hirsch receives $250k/month base salary ($400k/month if still interim after Dec 31, 2024); no severance or incentive plan eligibility.
Committee changes: Hirsch leaves Compensation & Compliance; Paul Herendeen joins Compensation, Sophia Langlois chairs it and joins Compliance.
Board retained Spencer Stuart to assist CEO search; company reiterates focus on relisting and portfolio execution.

item 5.02 item 8.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Blaise Coleman

President and Chief Executive Officer

Endo LP

Effective: 2024-08-29
Successor: Scott Hirsch
Filed: August 27, 2024, 7:59 PM ET

On August 25, 2024, the Board of Directors (the “Board”) of Endo, Inc. (the “Company”) determined that Blaise Coleman will no longer serve as the Company’s President and Chief Executive Officer, effective August 29, 2024.

Appointed (interim)

Scott Hirsch

Interim Chief Executive Officer

Endo LP

Effective: 2024-08-29
Filed: August 27, 2024, 7:59 PM ET

The Board has appointed Scott Hirsch, currently a Board member, to serve as the Company’s Interim Chief Executive Officer (“Interim CEO”), effective August 29, 2024.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Blaise Coleman departed as President and Chief Executive Officer at Endo LP.

Action: no longer serve
Role: President and Chief Executive Officer

Exact text from the filing

On August 25, 2024, the Board of Directors (the “Board”) of Endo, Inc. (the “Company”) determined that Blaise Coleman will no longer serve as the Company’s President and Chief Executive Officer, effective August 29, 2024.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Scott Hirsch was appointed as Interim Chief Executive Officer at Endo LP.

Action: appointed
Role: Interim Chief Executive Officer

Exact text from the filing

The Board has appointed Scott Hirsch, currently a Board member, to serve as the Company’s Interim Chief Executive Officer (“Interim CEO”), effective August 29, 2024.

View on SEC.gov

Source: SEC EDGAR

accession 0000950103-24-012639

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.